Market Overview

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Related IDXX
T. Rowe Price Reports 10.7% Stake In Idexx Labs
IDEXX Labs Sees One-Time Reduction In Operating Profit of $16M To $20M
Related NEOG
Ebola Vaccine Contenders
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year.

Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter.

Neogen (NASDAQ: NEOG) is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%.

Meridian Bioscience (NASDAQ: VIVO) is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%.

Abaxis (NASDAQ: ABAX) may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.

Posted-In: Diagnostic Substances Industry Highest Revenue Estimates NASDAQ StocksTrading Ideas

 

Related Articles (ABAX + IDXX)

Around the Web, We're Loving...

Get Benzinga's Newsletters